Pharmaceutical Business review

Eisai wins approval for GERD drug

Included in the submission was a 12-week, multi-center, open-label, randomized, parallel-group study of 111 adolescent gastroesophageal reflux disease (GERD) patients.

In this study, Aciphex was well tolerated in adolescent subjects, with a safety profile similar to that of adults. Efficacy results demonstrated that once-daily treatment with Aciphex 20mg for eight weeks reduced the severity and frequency of GERD symptoms compared to symptoms prior to treatment.